Vol 9, No 3 (2024)
Letter to the Editor
Published online: 2024-09-25
GLP-1 receptor agonists’ Role in the treatment of binge eating and bulimia nervosa
1
, 1, 1, 1
, 1, 1, 1
DOI: 10.5603/mrj.102177
Med Res J 2024;9(3):317-318.
Abstract
None
Keywords: Bulimia NervosaBinge EatingGLP-1 Receptor AgonistTreatment
References
- Kessler RC, Berglund PA, Chiu WT, et al. The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys. Biol Psychiatry. 2013; 73(9): 904–914.
- McElroy SL, Mori N, Guerdjikova AI, et al. Would glucagon-like peptide-1 receptor agonists have efficacy in binge eating disorder and bulimia nervosa? A review of the current literature. Med Hypotheses. 2018; 111: 90–93.
- Harry N, Anona K, Obitulata-Ugwu V, et al. Potential Role of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist in the Treatment of Bulimia Nervosa. Journal of Advances in Medicine and Medical Research. 2024; 36(7): 379–389.
- Richards J, Bang N, Ratliff EL, et al. Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study. Obes Pillars. 2023; 7: 100080.
- Aoun L, Almardini S, Saliba F, et al. GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review. J Clin Transl Endocrinol. 2024; 35: 100333.
- Robert SA, Rohana AG, Shah SA, et al. Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - A pilot study. Obes Res Clin Pract. 2015; 9(3): 301–304.